Crossmark

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1007/s00044-026-03606-6

Published Online: 2026-08-18

Published Print: 2026-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Sumi https://orcid.org/0000-0002-2257-0798
Hu, Longqin https://orcid.org/0000-0002-1799-5652
License Information

Text and Data Mining valid from 2026-08-18

Version of Record valid from 2026-08-18
More Information

Article History

Received: 29 July 2026

Accepted: 3 August 2026

First Online: 18 August 2026

Declarations

Conflict of interest: The authors declare no competing interests.